Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 28, 2010; 16(32): 4047-4054
Published online Aug 28, 2010. doi: 10.3748/wjg.v16.i32.4047
Published online Aug 28, 2010. doi: 10.3748/wjg.v16.i32.4047
Figure 3 Effects of AG825 on cholangiocarcinoma cell invasion, motility and proliferation.
A-C: Cells resuspended in medium that contained 0.2% fetal bovine serum (FBS) and indicated concentrations of AG825 were plated in the upper compartment of a Transwell chamber coated with and without Matrigel, for invasion and motility assays. After 6 h incubation, numbers of invading/motile cells were counted. Cells treated with the same vehicle were used as controls. Cell survival after 6 h of AG825 treatment was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay; D: Cells were treated with various concentrations of AG825 in 10% FBS medium for 72 h, and cell survival was determined using the MTT assay. Data are presented as mean ± SE of the percentage relative to the controls obtained from three separate experiments, each done in duplicate. aP < 0.05, bP < 0.01, dP < 0.001 vs control.
- Citation: Treekitkarnmongkol W, Suthiphongchai T. High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol 2010; 16(32): 4047-4054
- URL: https://www.wjgnet.com/1007-9327/full/v16/i32/4047.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i32.4047